AG

AgomAb Therapeutics N.V. American Depositary Shares

AGMB · Nasdaq

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for AgomAb Therapeutics N.V. American Depositary Shares in 2026. The next earnings report is expected on September 2, 2026.

Scheduled earnings dates

02 Sep 2026 02 Dec 2026 03 Mar 2027

Earnings calendar

Next earnings date

02 Sep 2026

In 13 days

EPS estimate

-0.38

Revenue estimate

0

Past earnings

06 Aug 2026
EPS actual
-0.37 (+2.6%)
estimate -0.38
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
03 Jun 2026
EPS actual
-0.45 (-6.8%)
estimate -0.42
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
25 Feb 2026
EPS actual
-0.52
estimate -0.49
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

AgomAb Therapeutics N.V. beat consensus estimates in its latest earnings report, with EPS of $-0.3735 versus an estimate of $-0.3834 and revenue of $0.00 meeting expectations. In the previous report EPS missed expectations while revenue met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Sector
Healthcare
Industry
Biotechnology
Country
Belgium
Exchange
Nasdaq
CEO
Tim Knotnerus
Employees
57
IPO date
29 May 2024
ISIN
US00860C1027
Website
agomab.com

Frequently asked questions

When does AgomAb Therapeutics N.V. American Depositary Shares (AGMB) next report earnings?

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) is scheduled to report earnings on September 2, 2026.

What was AgomAb Therapeutics N.V. American Depositary Shares's most recent earnings date?

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) last reported earnings on August 6, 2026.

Where is AgomAb Therapeutics N.V. American Depositary Shares stock listed?

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) is listed on Nasdaq.